Emergence of BCR-ABL1 (p190) in Acute Myeloid Leukemia Post-Gilteritinib Therapy

참고문헌 (9)

1. Papaemmanuil E, "Genomic classification and prognosis in acute myeloid leukemia", N Engl J Med, 374, pp.2209~2221 (2016)
2. Daver N, "Targeting FLT3 mutations in AML : review of current knowledge and evidence", Leukemia, 33, pp.299~312 (2019)
3. Pulte ED, "FDA approval summary : gilteritinib for relapsed or refractory acute myeloid leukemia with a FLT3 mutation", Clin Cancer Res, 27, pp.3515~3521 (2021)
4. McMahon CM, "Clonal selection with RAS pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia", Cancer Discov, 9, pp.1050~1063 (2019)
5. Piloto O, "Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways", Blood, 109, pp.1643~1652 (2007)
6. Kropp EM, "Mechanisms of resistance to targeted therapies for relapsed or refractory acute myeloid leukemia", Exp Hematol, 111, pp.13~24 (2022)
7. Swerdlow SH, "World Health Organization classification of tumours of haematopoietic and lymphoid tissues" (2017), IARC
8. Alotaibi AS, "Emergence of BCR–ABL1 fusion in AML post-FLT3 inhibitor-based therapy : a potentially targetable mechanism of resistance – a case series", Front Oncol, 10, pp.588876~ (2020)
9. Staudt D, "Targeting oncogenic signaling in mutant FLT3 acute myeloid leukemia : the path to least resistance", Int J Mol Sci, 19, pp.3198~ (2018)

관련 논문AI추천